Dewpoint Therapeutics GmbH

Tatzberg 47
01307 Dresden
Germany

Website: www.dewpointx.com

Industry sector: Biotechnology
Products/services: Drug discovery and development
Location(s): Dresden, Frankfurt am Main, Boston
Date of foundation: 2018
Number of employees: 130
About the company/organisation: Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. We believe that a vast range of conditions arise from the dysfunction or aberrant composition of condensates (condensatopathy) — including cancer, neurodegeneration, cardiopulmonary disorders, and metabolic disease. We are employing our integrated wet lab/machine learning platform to identify a suite of condensate-modulators (c-mods) with the potential to alter the course of these diseases. Our scientists work in Boston, Dresden, and Frankfurt to translate condensate biology into treatments for the toughest diseases.
Learn more at dewpointx.com, and follow us on Twitter and LinkedIn.
Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.

Recruitments per year: 30
Area of expertise:

Biological Sciences

Biochemistry

Biotechnology

Chemistry

Pharmaceutics

Medicine

Engineering

Computer Sciences

Last degree:

PostDoc

PhD

Master

Bachelor

Technical assistance

Translational medicine

Desired additional skills (soft skills): fluent English
Career opportunities: All levels
Trainee program: No
Contact: Tatzberg 47
Dewpoint Therapeutics GmbH